312 related articles for article (PubMed ID: 9230202)
1. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
Siim BG; Menke DR; Dorie MJ; Brown JM
Cancer Res; 1997 Jul; 57(14):2922-8. PubMed ID: 9230202
[TBL] [Abstract][Full Text] [Related]
2. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes.
Evans JW; Yudoh K; Delahoussaye YM; Brown JM
Cancer Res; 1998 May; 58(10):2098-101. PubMed ID: 9605751
[TBL] [Abstract][Full Text] [Related]
3. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
Dorie MJ; Kovacs MS; Gabalski EC; Adam M; Le QT; Bloch DA; Pinto HA; Terris DJ; Brown JM
Neoplasia; 1999 Nov; 1(5):461-7. PubMed ID: 10933062
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
[TBL] [Abstract][Full Text] [Related]
5. Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice.
Olive PL; Vikse CM; Banath JP
Cancer Res; 1996 Oct; 56(19):4460-3. PubMed ID: 8813141
[TBL] [Abstract][Full Text] [Related]
6. Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.
Yang B; Reynolds CP
Clin Cancer Res; 2005 Apr; 11(7):2774-80. PubMed ID: 15814660
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
el-Said A; Menke D; Dorie MJ; Brown JM
Radiat Oncol Investig; 1999; 7(3):163-9. PubMed ID: 10406058
[TBL] [Abstract][Full Text] [Related]
8. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DNA replication by tirapazamine.
Peters KB; Wang H; Brown JM; Iliakis G
Cancer Res; 2001 Jul; 61(14):5425-31. PubMed ID: 11454687
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia.
Masunaga S; Ono K; Hori H; Akaboshi M; Kawai K; Suzuki M; Kinashi Y; Kasai S; Nagasawa H; Uto Y
Radiat Med; 1998; 16(6):441-8. PubMed ID: 9929144
[TBL] [Abstract][Full Text] [Related]
11. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
[TBL] [Abstract][Full Text] [Related]
12. Reduction of tumor hypoxia and inhibition of DNA repair by nicotinamide after irradiation of SCCVII murine tumors and normal tissues.
Zheng H; Olive PL
Cancer Res; 1996 Jun; 56(12):2801-8. PubMed ID: 8665517
[TBL] [Abstract][Full Text] [Related]
13. Potentially lethal damage repair by total and quiescent tumor cells following various DNA-damaging treatments.
Masunaga S; Ono K; Hori H; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y
Radiat Med; 1999; 17(4):259-64. PubMed ID: 10510897
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status.
Masunaga S; Ono K; Takahashi A; Ohnishi K; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Nagasawa H; Uto Y; Hori H
Cancer Sci; 2003 Jan; 94(1):125-33. PubMed ID: 12708486
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.
Hay MP; Pchalek K; Pruijn FB; Hicks KO; Siim BG; Anderson RF; Shinde SS; Phillips V; Denny WA; Wilson WR
J Med Chem; 2007 Dec; 50(26):6654-64. PubMed ID: 18052317
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
Yang B; Keshelava N; Anderson CP; Reynolds CP
Cancer Res; 2003 Apr; 63(7):1520-6. PubMed ID: 12670899
[TBL] [Abstract][Full Text] [Related]
18. Tirapazamine: laboratory data relevant to clinical activity.
Brown JM; Wang LH
Anticancer Drug Des; 1998 Sep; 13(6):529-39. PubMed ID: 9755717
[TBL] [Abstract][Full Text] [Related]
19. Exploring vascular dysfunction caused by tirapazamine.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Microvasc Res; 2008 Mar; 75(2):247-55. PubMed ID: 18023823
[TBL] [Abstract][Full Text] [Related]
20. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
